IOVANCE BIOTHERAPEUTICS, INC. Share-based Payment Arrangement, Expense
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Share-based Payment Arrangement, Expense of $100.00 thousand for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2020-11-05
- IOVANCE BIOTHERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2019-09-30 was $100.00K, a 0.00% change year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2018-09-30 was $100.00K.
- IOVANCE BIOTHERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2017-03-31 was $0.00, a 100.00% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
- IOVANCE BIOTHERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2016 was $1.00M, a 44.44% decline from fiscal 2015.
- IOVANCE BIOTHERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2015 was $1.80M, a 38.46% increase from fiscal 2014.
- IOVANCE BIOTHERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2014 was $1.30M, a 85.71% increase from fiscal 2013.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 3 month as first filed | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 6 month as first filed | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month | Share-based Payment Arrangement, Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $100.00K 10-Q · filed 2020-11-05 | |||||
| 2020-06-30 | $100.00K 10-Q · filed 2020-08-06 | ||||||
| 2019-09-30 | $100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $200.00K 10-Q · filed 2020-11-05 | |||||
| 2019-06-30 | $100.00K 10-Q · filed 2020-08-06 | ||||||
| 2018-09-30 | $100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $200.00K 10-Q · filed 2019-11-04 | |||||
| 2018-06-30 | $100.00K 10-Q · filed 2019-08-01 | ||||||
| 2017-12-31 | $0.00 10-K · filed 2018-03-12 | ||||||
| 2017-03-31 | $0.00 10-Q · filed 2017-05-03 | ||||||
| 2016-12-31 | $1.00M 10-K · filed 2019-02-28 | ||||||
| 2016-06-30 | $4.50M 10-Q · filed 2016-08-09 | $6.10M 10-Q · filed 2016-08-09 | |||||
| 2016-03-31 | $300.00K 10-Q · filed 2017-05-03 | $1.50M 10-Q · filed 2016-05-09 | |||||
| 2015-12-31 | $1.80M 10-K · filed 2018-03-12 | $6.70M 10-K · filed 2016-03-11 | |||||
| 2015-06-30 | $1.30M 10-Q · filed 2016-08-09 | $2.30M 10-Q · filed 2016-08-09 | $2.30M 10-Q · filed 2015-08-10 | ||||
| 2015-03-31 | $1.02M 10-Q · filed 2015-05-11 | ||||||
| 2014-12-31 | $1.30M 10-K · filed 2017-03-09 | $2.60M 10-K · filed 2016-03-11 | |||||
| 2014-06-30 | $438.95K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $1.34M 10-Q · filed 2015-08-10 | |||||
| 2014-03-31 | $901.65K 10-Q · filed 2015-05-11 | ||||||
| 2013-12-31 | $700.00K 10-K · filed 2016-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |